The success of the Drug, Cosmetic and Toiletry Wholesaling industry is driven by the nondiscretionary nature of its primary product: pharmaceuticals. Although industry demand is booming, the patent cliff that preceded this period has limited industry growth. A number of major brand-name drugs have lost patent exclusivity over the past five years, creating an opportunity for less-expensive generic drugs to join the market. Nevertheless, wholesalers have prepared for the expanded use of generic drugs and adjusted their prices and supplies accordingly over the past few years. The effects of various newly introduced regulation as well as changes in the supply of generic and branded pharmaceuticals will characterize the industry's outlook. While the Patient Protection and Affordable Care Act (PPACA) is expected to continue to benefit the industry through increased insurance coverage for many Americans, many private and national insurance programs such as Medicaid support less-expensive generic brands of drugs, in order to lower the amount insurers pay for medical bills.
Drug, cosmetic and toiletry wholesalers primarily distribute pharmaceutical products intended for internal and external consumption, such as tablets, capsules, vials, ointments and powders. The industry includes a range of biological and medical products, and botanical drugs and herbs. The industry does not include businesses that primarily distribute surgical, dental or hospital equipment.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.